PYGO2 ablation promotes lymphoid organization and STING-dependent antitumor immunity in prostate cancer
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Yini Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Harper Cancer Research Institute, Boler-Parseghian Center for Rare Diseases, University of Notre Dame, Notre Dame,…. Hauptthemen laut MEDLINE: Membrane Proteins, Prostatic Neoplasms, Tertiary Lymphoid Structures, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Elsa U. Pardee Foundation, National Institutes of Health.
Abstract (Originalsprache)
Prostate cancer is an immunologically cold tumor with a limited response to immune checkpoint blockade. Although tertiary lymphoid structures (TLSs) are associated with favorable immunotherapeutic outcomes in various malignancies, the tumor-intrinsic mechanisms governing their formation in prostate cancer remain poorly defined. We investigated whether the frequently amplified chromatin effector PYGO2 regulates lymphoid organization and antitumor immunity. Using prostate-specific Pten/Smad4 double-knockout and Pten/Smad4/Pygo2 triple-knockout mice, syngeneic tumors, transcriptomics, single-cell RNA sequencing, and immunostaining, we found that Pygo2 ablation restored androgen receptor signaling, reduced neuroendocrine-associated features, delayed castration-resistant progression, and prolonged survival. Pygo2-deficient tumors expressed higher levels of tertiary lymphoid structure (TLS)-associated chemokines, exhibited greater T- and B-cell infiltration, and developed TLS-like structures. Single-cell profiling showed increased CD8/Treg ratios, B-cell abundance, TLS imprint scores, and antigen-presentation signatures, particularly after combination therapy. Pygo2 loss also increased DNA damage and was accompanied by activation of the STING-interferon axis. In RM1 syngeneic tumors, STING silencing attenuated the Pygo2-loss-associated increase in cytokine expression, immune infiltration, apoptosis, and tumor control. Combining Pygo2 ablation with castration, CXCR1/2 inhibition, and dual PD-1/CTLA-4 blockade produced durable disease control in more than 80% of Pygo2-deficient mice. These findings identify PYGO2 as a tumor-intrinsic regulator of castration resistance and antitumor immunity and support combining PYGO2-directed strategies with androgen deprivation, myeloid suppression, and immune checkpoint blockade in prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Harper Cancer Research Institute, Boler-Parseghian Center for Rare Diseases, University of Notre Dame, Notre Dame, IN, 46556, USA; Integrated Biomedical Science Graduate Program, Unive…
- Department of Biological Sciences, Harper Cancer Research Institute, Boler-Parseghian Center for Rare Diseases, University of Notre Dame, Notre Dame, IN, 46556, USA.
- Department of Medical and Molecular Genetics, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA; Department of BioHealth Informatics, Luddy School o…
- Department of Pathology and Laboratory Medicine, Department of Surgery, Brown University Warren Alpert Medical School, The Legorreta Cancer Center at Brown University, and Brown University Health, Providence, RI, USA.
Förderung
- Elsa U. Pardee Foundation
- National Institutes of Health
Zitieren
APA
Zhu, Y., Liu, Y., Zeng, Z., Huo, Q., Liang, M., Wang, S., Barupala, N., Lu, X., Wan, J., Cheng, L., & Lu, X. (2026). PYGO2 ablation promotes lymphoid organization and STING-dependent antitumor immunity in prostate cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218862
Vancouver
Zhu Y, Liu Y, Zeng Z, Huo Q, Liang M, Wang S, et al. PYGO2 ablation promotes lymphoid organization and STING-dependent antitumor immunity in prostate cancer. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218862
BibTeX
@article{Zhu2026,
author = {Zhu, Yini and Liu, Yan and Zeng, Ziyu and Huo, Qi and Liang, Minzhi and Wang, Shiyu and Barupala, Nipuni and Lu, Xuemin and Wan, Jun and Cheng, Liang and Lu, Xin},
title = {PYGO2 ablation promotes lymphoid organization and STING-dependent antitumor immunity in prostate cancer},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218862}
}
EUVIMED